Acurx (ACXP) files Certificate of Amendment on Sept 19, 2025

Acurx Pharmaceuticals, Inc. filed a Form 8-K dated September 22, 2025 reporting a material event: the company attached a Certificate of Amendment to the Certificate of Incorporation that is dated September 19, 2025.

Rhea-AI Filing Summary

Acurx Pharmaceuticals, Inc. filed a Form 8-K dated September 22, 2025 reporting a material event: the company attached a Certificate of Amendment to the Certificate of Incorporation that is dated September 19, 2025. The filing notes inclusion of the cover page Inline XBRL tags and is signed by David P. Luci, President and Chief Executive Officer. The report appears limited to the corporate charter amendment and related filing mechanics; no financial statements, earnings data, or transaction details are included in the provided text.

Positive

• Certificate of Amendment filed on September 19, 2025, showing corporate formalities were completed
• Form 8-K was signed by the CEO, David P. Luci, indicating executive acknowledgement

Negative

• None.

Insights

Corporate Governance Analyst

Company filed a corporate charter amendment on Sept 19, 2025.

The submission of a Certificate of Amendment updates the company’s governing documents; such amendments typically affect capitalization, share structure, or governance terms.

The filing text provided does not specify what clause was amended, so investors cannot determine immediate effects on equity structure or voting rights from this document alone.

8-K Event Classification

2 items: 5.03, 9.01

2 items

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ACXP report in the Form 8-K dated September 22, 2025?

The filing reports a Certificate of Amendment to the Certificate of Incorporation dated September 19, 2025 and includes Inline XBRL cover page tags.

Does the 8-K disclose the specific changes to Acurx's charter?

No. The provided text names the Certificate of Amendment but does not describe the specific amendments or affected charter provisions.

Who signed the Form 8-K for Acurx (ACXP)?

The Form 8-K is signed by David P. Luci, President and Chief Executive Officer.

Is there any financial or transaction detail in this 8-K?

No. The excerpt contains no financial tables, earnings data, or transaction descriptions.

When was the Certificate of Amendment dated?

The Certificate of Amendment is dated September 19, 2025 as reported in the 8-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/22/2025 - 04:42 PM Learn about SEC filing dates

false --12-31 0001736243 0001736243 2025-09-22 2025-09-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 22, 2025

Acurx Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40536		82-3733567
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

259 Liberty Avenue, Staten Island, NY 10305

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (917) 533-1469

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ACXP		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

At the special meeting of stockholders of Acurx Pharmaceuticals, Inc. (the “Company”) held on September 16, 2025, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Certificate of Incorporation, as amended, to increase the total number of authorized shares of the Company’s common stock from 200,000,000 to 250,000,000. On September 22, 2025, the Company filed the Amendment with the Secretary of State of the State of Delaware with immediate effect.

The summary of the Amendment contained herein does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached as Exhibit 3.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.		Description
3.1		Certificate of Amendment to the Certificate of Incorporation, as amended, dated September 19, 2025
104		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

	Acurx Pharmaceuticals, Inc.
Date: September 22, 2025
	By:	/s/ David P. Luci
	Name:	David P. Luci
	Title:	President and Chief Executive Officer